GLP-1 Receptor Agonists: Efficacy, Safety, and Neurological Frontiers

These papers provide a comprehensive overview of GLP-1 and dual GLP-1/GIP receptor agonists, highlighting their transformative role in treating type 2 diabetes and obesity. The texts detail the pharmacology and dosing of specific agents like semaglutide and tirzepatide, comparing their effectiveness in glycemic control and weight loss. Beyond metabolic health, the research explores emerging neurological benefits, investigating how these drugs might protect against stroke, Alzheimer’s, and Parkinson’s disease. While emphasizing clinical advantages such as cardiovascular and renal protection, the authors also address adverse effects like gastrointestinal distress and rare safety risks. Overall, the documents synthesize evidence from clinical trials to illustrate the expanding therapeutic landscape of incretin mimetics.